Welcome to our dedicated page for ORAMED PHARMACEUTICALS SEC filings (Ticker: ORMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oramed Pharmaceuticals Inc. reports material events and financial information through SEC filings that document its oral drug delivery business, investment-related agreements, and capital actions. Recent 8-K disclosures cover operating and financial results, option and warrant-related arrangements, payments tied to strategic investments, cash dividends, and material definitive agreements involving company assets and subsidiaries.
The filings also document Oramed’s common stock registration on the Nasdaq Capital Market and Tel Aviv Stock Exchange, its shareholder rights agreement, board-authorized distributions, and other capital-structure and governance matters. These records connect the company’s clinical-stage POD technology platform and oral insulin program with formal disclosures on liquidity, securities, contractual rights, and corporate events.
Oramed Pharmaceuticals, Inc. reports condensed consolidated interim results and disclosures for the quarter ended June 30, 2025. The company operates in a single reportable segment focused on research and development of orally delivered pharmaceuticals and vaccines. The filing details multiple strategic investments and financing arrangements, including a $36,900 investment in Alpha Tau Medical (yielding an unrealized gain of $7,138 recognized in the six months ended June 30, 2025), equity method accounting for a 50% interest in RoyaltyVest, and various loans and real estate investments presented at fair value.
The company continues to hold structured receivables and convertible notes related to Scilex, including Tranche A and Tranche B Notes, and warrants (including 6,500,000 Subsequent Penny Warrants) with monetization restrictions; as of June 30, 2025 Scilex had repaid $69,200 of the Tranche A Note. The company entered an Option Agreement (July 22, 2025) under which Scilex may repurchase Subsequent Penny Warrants for a total of $27,000, and the agreement could extend the Tranche A Note maturity if completed. The company discloses deferred revenue recognition related to an HTIT license arrangement and describes cash flows, fair value measurements, share-based compensation grants (PSUs/RSUs), and a limited stock repurchase program under which 163,869 shares were repurchased for $371.
Oramed Pharmaceuticals (ORMP) filed an 8-K disclosing an Option Agreement signed 22-Jul-25 with Scilex Holding. The accord gives Scilex the right to repurchase Oramed’s remaining 6.5 M “Penny Warrants” (exercise price $0.01/sh) in two tranches for a total cash consideration of $27 M. To secure the option, Scilex will pay Oramed $1.5 M in two equal installments due 8-Aug-25 and 16-Dec-25.
- Tranche 1: up to 3.13 M warrants for $13 M if exercised by 30-Sep-25.
- Tranche 2: up to 3.37 M warrants for $14 M if exercised by 31-Dec-25.
If Scilex completes the repurchase and makes all payments, the maturity of the $101.9 M Tranche A senior secured note held by Oramed will be extended to 31-Mar-26 and its make-whole prepayment penalty waived.
Until the earlier of option expiry or termination, Oramed has agreed not to exercise the warrants. Oramed can terminate the agreement if Scilex misses any payment or fails to exercise by the set dates. Post-termination, Scilex will seek shareholder approval to permit stock issuance above a 19.9 % cap should Oramed later exercise retained warrants.
The filing also clarifies prior disclosure: despite Scilex’s 1-for-35 reverse split, the Penny Warrant exercise price remains $0.01 and the quantity remains 6.5 M shares; no impact to previously reported Q1-25 financials.